Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …
2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations
Introduction Clopidogrel is the most frequently utilized P2Y12 inhibitor and is characterized
by broad interindividual response variability resulting in impaired platelet inhibition and …
by broad interindividual response variability resulting in impaired platelet inhibition and …
[HTML][HTML] MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: a review
P Czajka, A Fitas, D Jakubik, C Eyileten… - Frontiers in …, 2021 - frontiersin.org
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by
specific gene modifications. Platelets are the major source for circulating miRNAs, with …
specific gene modifications. Platelets are the major source for circulating miRNAs, with …
Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES
KH Chau, AJ Kirtane, RM Easterwood… - Cardiovascular …, 2021 - jacc.org
Objectives The aim of this study was to determine the risk period for increased stent
thrombosis (ST) after percutaneous coronary intervention (PCI) in patients with acute …
thrombosis (ST) after percutaneous coronary intervention (PCI) in patients with acute …
Guided P2Y12 inhibitor therapy after percutaneous coronary intervention
D Sibbing, A Kastrati - The Lancet, 2021 - thelancet.com
2 McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
rhesus macaques. Nature 2021; 590: 630–34. 3 Yu J, Tostanoski LH, Peter L, et al. DNA …
rhesus macaques. Nature 2021; 590: 630–34. 3 Yu J, Tostanoski LH, Peter L, et al. DNA …
[HTML][HTML] Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy: Impact of HPR on clopidogrel …
S Lee, S Lee, W Chun, Y Song, SH Choi… - …, 2021 - ncbi.nlm.nih.gov
Background Although P2Y 12 inhibitor monotherapy has emerged as a promising
alternative for dual antiplatelet therapy (DAPT), there remains concern regarding the safety …
alternative for dual antiplatelet therapy (DAPT), there remains concern regarding the safety …
[HTML][HTML] CHADS2 and CHA2DS2-VASc scores as predictors of platelet reactivity in acute coronary syndrome
Background Platelet function testing (PFT) in patients treated with P2Y 12 inhibitors has
been widely evaluated for the prediction of stent thrombosis, myocardial infarction, and …
been widely evaluated for the prediction of stent thrombosis, myocardial infarction, and …
Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
W Chen, C Zhang, J Zhao, X Xu, H Dang… - Clinical …, 2021 - Wiley Online Library
Background Clopidogrel, prasugrel and ticagrelor, acting on platelet P2Y12 receptor, are
commonly used for prevention of stent thrombosis (ST) among patients who underwent …
commonly used for prevention of stent thrombosis (ST) among patients who underwent …